Your browser is no longer supported. Please, upgrade your browser.
Settings
MNOV MediciNova, Inc. daily Stock Chart
MNOV [NASD]
MediciNova, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own1.80% Shs Outstand41.30M Perf Week-3.60%
Market Cap375.83M Forward P/E- EPS next Y-0.87 Insider Trans0.00% Shs Float37.09M Perf Month1.90%
Income-13.00M PEG- EPS next Q-0.11 Inst Own23.70% Short Float7.18% Perf Quarter-7.89%
Sales- P/S- EPS this Y3.50% Inst Trans-6.33% Short Ratio25.75 Perf Half Y-16.51%
Book/sh1.82 P/B5.00 EPS next Y-97.70% ROA-21.60% Target Price20.00 Perf Year83.47%
Cash/sh1.55 P/C5.85 EPS next 5Y20.00% ROE-23.20% 52W Range4.78 - 14.50 Perf YTD40.65%
Dividend- P/FCF- EPS past 5Y13.70% ROI- 52W High-37.24% Beta0.22
Dividend %- Quick Ratio41.20 Sales past 5Y- Gross Margin- 52W Low90.38% ATR0.39
Employees9 Current Ratio41.20 Sales Q/Q- Oper. Margin- RSI (14)48.87 Volatility3.90% 4.24%
OptionableYes Debt/Eq0.00 EPS Q/Q6.00% Profit Margin- Rel Volume0.72 Prev Close8.93
ShortableYes LT Debt/Eq0.00 EarningsAug 15 Payout- Avg Volume103.38K Price9.10
Recom1.50 SMA20-2.11% SMA502.78% SMA200-1.41% Volume74,427 Change1.90%
Mar-28-18Initiated B. Riley FBR, Inc. Buy $22
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
May-15-08Initiated Rodman & Renshaw Mkt Outperform $9
Jul-09-07Initiated Punk, Ziegel & Co Buy $22
Aug-06-18 07:00PM  MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge GlobeNewswire
Jul-31-18 07:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK GlobeNewswire
Jul-29-18 07:00PM  MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial GlobeNewswire
Jul-25-18 09:15AM  MNOV: Plenty of Cash to Advance Pipeline Forward Zacks Small Cap Research
Jul-12-18 09:30AM  MNOV: Encouraging Data from Subgroup Analysis of ALS Study Zacks Small Cap Research
Jul-09-18 07:00PM  MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Jun-19-18 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan GlobeNewswire
Jun-05-18 07:35AM  Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-31-18 07:14PM  When Will MediciNova Inc (NASDAQ:MNOV) Become Profitable? Simply Wall St.
May-16-18 03:55PM  Want To Invest In MediciNova Inc (NASDAQ:MNOV)? Heres How It Performed Lately Simply Wall St.
May-09-18 07:00PM  MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma GlobeNewswire
May-08-18 07:00PM  MediciNova to Present at the UBS Global Healthcare Conference in New York GlobeNewswire
May-07-18 07:00PM  MediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal GlobeNewswire
May-01-18 09:20AM  MNOV: Additional Data Presented for MN-166 in MS and ALS Zacks Small Cap Research
Apr-26-18 07:00PM  MediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual Meeting GlobeNewswire
Apr-24-18 06:30AM  MediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data GlobeNewswire -5.05%
Apr-13-18 08:30AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  MediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France GlobeNewswire
Apr-12-18 08:20AM  Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-06-18 12:55PM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-03-18 07:20AM  Wired News MediciNova Released Results of Phase-2 Clinical Trial Assessing MN-166 (ibudilast) in Methamphetamine Dependence ACCESSWIRE
Apr-02-18 04:30PM  Why Limelight Networks, MediciNova, and Commvault Systems Jumped Today Motley Fool +18.88%
02:53PM  Here's Why MediciNova Jumped as Much as 26.2% Today Motley Fool
10:04AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Apr-01-18 07:00PM  MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis GlobeNewswire
Mar-29-18 06:30AM  MediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence GlobeNewswire -14.55%
Mar-28-18 07:00PM  MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy GlobeNewswire
Mar-15-18 08:15AM  Report: Exploring Fundamental Drivers Behind Reading International, Rhythm Pharmaceuticals, Grupo Aeroportuario del Centro Norte S.A.B. de C.V., Golar LNG, Central European Media Enterprises, and MediciNova New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-12-18 07:00PM  MediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo GlobeNewswire
Feb-21-18 06:18PM  Is MediciNova Inc (NASDAQ:MNOV) A Good Healthcare Bet? Simply Wall St.
Feb-18-18 06:00PM  MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California GlobeNewswire
Feb-16-18 10:30AM  MNOV: Raises $40 Million in Underwritten Public Offering Zacks Small Cap Research
Feb-12-18 06:30PM  MediciNova Announces Closing of Underwritten Public Offering of Common Stock GlobeNewswire
Feb-08-18 01:17PM  Here's Why MediciNova, Inc. Stock Is Sliding Today Motley Fool -11.41%
Feb-07-18 07:12PM  MediciNova Announces Pricing of Underwritten Public Offering of Common Stock GlobeNewswire -9.49%
04:01PM  MediciNova Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
10:00AM  MNOV: MN-166 Shows 26% Reduction in Disability Progression in Progressive MS Phase 2 Study Zacks Small Cap Research
Feb-05-18 07:00AM  Blog Exposure - MediciNovas MN-166 Shows Reduction in Confirmed Disability Progression in SPRINT-MS Phase-2b Trial ACCESSWIRE
Feb-01-18 06:00PM  MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease Drug GlobeNewswire +8.82%
Jan-31-18 07:00AM  MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San Diego GlobeNewswire +6.25%
Jan-30-18 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California GlobeNewswire
Jan-28-18 06:00PM  MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France GlobeNewswire
Jan-16-18 06:00PM  MediciNova to Present at the 98th Annual Meeting of the Chemical Society of Japan GlobeNewswire
02:04PM  What You Must Know About MediciNova Incs (NASDAQ:MNOV) Major Investors Simply Wall St.
Jan-09-18 07:13AM  Does MediciNova Incs (NASDAQ:MNOV) CEO Pay Compared Well With Peers? Simply Wall St.
Jan-01-18 05:25PM  MediciNova Inc (NASDAQ:MNOV): Whats The Analyst Consensus Outlook? Simply Wall St.
Dec-22-17 08:05PM  Does MediciNova Incs (NASDAQ:MNOV) Past Performance Indicate A Stronger Future? Simply Wall St.
Dec-13-17 11:40AM  MNOV: Positive Topline Results for MN-166 in P2 ALS Study Zacks Small Cap Research +10.02%
Dec-07-17 07:03PM  MediciNova stock up more than 50% on positive trial results MarketWatch
06:00PM  MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Nov-23-17 04:51PM  Is MediciNova Inc (MNOV) Cheap And High Growth? Simply Wall St.
Nov-10-17 01:30AM  MediciNova Appoints Hideki Nagao to its Board of Directors GlobeNewswire
Nov-09-17 06:00PM  MediciNova Announces Collaboration with the U.S. Department of Veterans Affairs and Oregon Health & Science University to Evaluate MN-166 (ibudilast) in Methamphetamine Use Disorder GlobeNewswire
Nov-08-17 06:59PM  Is MediciNova Inc (MNOV) Undervalued? Simply Wall St.
Nov-01-17 07:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA GlobeNewswire -9.99%
Oct-31-17 05:00PM  MNOV: Positive Results in Phase 2b Study of MN-166 in Progressive MS Zacks Small Cap Research
Oct-30-17 06:00AM  MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile GlobeNewswire
Oct-26-17 06:00AM  MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS:  Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability GlobeNewswire
Oct-17-17 08:05AM  MediciNova, Upcoming Phase II Data Presentation, Ibudilast Review ACCESSWIRE
Sep-19-17 06:00AM  MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence GlobeNewswire
Sep-18-17 07:00PM  MediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New York GlobeNewswire
Aug-30-17 06:00AM  MediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, France GlobeNewswire
Aug-01-17 12:00PM  MNOV: MN-166 Shows Activity in Preclinical Brain Cancer Study Zacks Small Cap Research
Jun-05-17 04:00PM  MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois GlobeNewswire
Apr-25-17 07:00PM  MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 69th Annual Meeting  in Boston GlobeNewswire
Apr-09-17 07:00PM  MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois GlobeNewswire
Feb-27-17 06:00PM  MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland GlobeNewswire +5.74%
12:00PM  MNOV: MN-166 Making Progress in Numerous Indications Zacks Small Cap Research
Feb-18-17 01:04PM  MEDICINOVA INC Financials
Feb-15-17 08:42AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Feb-14-17 06:26PM  MEDICINOVA INC Files SEC form 10-K, Annual Report
Feb-07-17 06:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston GlobeNewswire
Feb-06-17 06:00PM  MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research GlobeNewswire
Feb-01-17 06:00PM  MediciNova to Attend Mizuho Healthcare Conference in New York GlobeNewswire
Jan-23-17 06:00PM  MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence GlobeNewswire
Dec-22-16 11:30AM  MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion Zacks Small Cap Research
Dec-20-16 06:00PM  MediciNova Announces European Commission Grants Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire -6.52%
Dec-19-16 06:00AM  MediciNova Announces Phase 2b Trial of MN-166 (ibudilast) in Progressive MS will Continue as Planned Following DSMB Review of Interim Efficacy Analysis GlobeNewswire
Dec-15-16 10:32AM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016 Capital Cube
10:32AM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016
Dec-14-16 06:00AM  MediciNova Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-09-16 06:00AM  MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland GlobeNewswire
Nov-14-16 06:00AM  MediciNova to Present at the Piper Jaffray Healthcare Conference in New York GlobeNewswire +6.73%
Nov-10-16 05:02PM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:00AM  MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire
Nov-07-16 06:00PM  MediciNova to Attend Global Mizuho Investor Conference in New York GlobeNewswire
Oct-30-16 07:00PM  MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland GlobeNewswire
Oct-27-16 11:00AM  MNOV: Interim Analysis of MN-166 in Progressive MS in 4Q16; ODD granted to MN-166 for ALS Zacks Small Cap Research
Oct-26-16 10:20AM  MediciNova reports 3Q loss
06:05AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Oct-25-16 05:20PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Oct-11-16 07:00PM  MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis GlobeNewswire
02:35PM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016 Capital Cube
02:35PM  MediciNova, Inc. :MNOV-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016
Sep-25-16 07:00PM  Options on MediciNova Common Stock Listed on CBOE GlobeNewswire
Sep-16-16 05:17PM  MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Jul-29-16 12:00PM  MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16 Zacks Small Cap Research
Jul-27-16 06:12AM  MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure
Jul-26-16 05:18PM  MEDICINOVA INC Files SEC form 10-Q, Quarterly Report
Jul-24-16 07:00PM  MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis GlobeNewswire
MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IWAKI YUICHIPresident and CEOMar 05Option Exercise2.2050,003110,007740,594Mar 07 04:31 PM
IWAKI YUICHIPresident and CEOJan 03Option Exercise4.4253,363235,864690,591Jan 05 04:51 PM
Okajima MasatsuneVP and Head of Japanese OfficeDec 12Option Exercise4.4248,000212,160108,941Dec 14 03:03 PM
IWAKI YUICHIPresident and CEONov 02Option Exercise4.4221,06793,116637,228Nov 06 08:15 AM
Ishizaka YoshioDirectorAug 21Buy5.175,00025,85010,000Aug 23 01:50 PM